Marine Motte-La

Paris, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 29 publications

Treatment Discontinuation in MOGAD-One Size Does Not Fit All-Reply.

Treatment Discontinuation in MOGAD-One Size Does Not Fit All-Reply.

Journal: JAMA neurology
Published: August 31, 2026

Early corticosteroids predict visual whereas MRI lesion extent predicts retinal atrophy outcomes in MOG antibody-associated optic neuritis.

Early corticosteroids predict visual whereas MRI lesion extent predicts retinal atrophy outcomes in MOG antibody-associated optic neuritis.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: April 15, 2026

Treatment Discontinuation in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.

Treatment Discontinuation in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.

Journal: JAMA neurology
Published: March 23, 2026

Frequency of AQP4 and MOG Antibodies in Patients With Optic Neuritis Fulfilling Minimal New Multiple Sclerosis MRI Criteria.

Frequency of AQP4 and MOG Antibodies in Patients With Optic Neuritis Fulfilling Minimal New Multiple Sclerosis MRI Criteria.

Journal: Neurology
Published: March 17, 2026

Cladribine use for multiple sclerosis with autoimmune comorbidities: retrospective analysis of the French MS registry, case series, and therapeutic considerations.

Cladribine use for multiple sclerosis with autoimmune comorbidities: retrospective analysis of the French MS registry, case series, and therapeutic considerations.

Journal: Therapeutic advances in neurological disorders
Published: February 24, 2026

Outcomes After Acute Plasma Exchange for Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.

Outcomes After Acute Plasma Exchange for Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.

Journal: Neurology
Published: August 29, 2025

Risk of postpartum disease activity with subcutaneous versus intravenous Natalizumab in pregnant women with multiple sclerosis.

Risk of postpartum disease activity with subcutaneous versus intravenous Natalizumab in pregnant women with multiple sclerosis.

Journal: Multiple sclerosis and related disorders
Published: August 08, 2025

Ocrelizumab-induced neutropenia: severity, recurrence, and management. A French national pharmacovigilance study.

Ocrelizumab-induced neutropenia: severity, recurrence, and management. A French national pharmacovigilance study.

Journal: Multiple sclerosis and related disorders
Published: June 18, 2025

Rethinking routine lumbar puncture in isolated optic neuritis: results from a large cohort study.

Rethinking routine lumbar puncture in isolated optic neuritis: results from a large cohort study.

Journal: Journal of neurology
Published: June 17, 2025

Choroid plexus enlargement and Kappa light chains index reflect distinct pathophysiological processes in Multiple Sclerosis.

Choroid plexus enlargement and Kappa light chains index reflect distinct pathophysiological processes in Multiple Sclerosis.

Journal: Multiple sclerosis and related disorders
Published: April 03, 2025

Lack of efficacy of sofosbuvir in Human Pegivirus associated neurological disorders.

Lack of efficacy of sofosbuvir in Human Pegivirus associated neurological disorders.

Journal: Revue neurologique
Published: December 30, 2024

Long-Term Outcome and Prognosis of Idiopathic Optic Neuritis: A Cohort Study.

Long-Term Outcome and Prognosis of Idiopathic Optic Neuritis: A Cohort Study.

Journal: European journal of neurology
Published: September 24, 2024
Showing 1-12 of 29

Last Updated: 09/26/2026